Dyne Therapeutics, Inc.
DYN
$12.40
$0.161.31%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 98.98% | 89.83% | 66.73% | 68.25% | 11.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 42.01% | 46.52% | 39.28% | 47.17% | 41.65% |
| Operating Income | -42.01% | -46.52% | -39.28% | -47.17% | -41.65% |
| Income Before Tax | -34.54% | -41.51% | -36.08% | -45.67% | -40.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -34.54% | -41.51% | -36.08% | -45.67% | -40.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -34.54% | -41.51% | -36.08% | -45.67% | -40.36% |
| EBIT | -42.01% | -46.52% | -39.28% | -47.17% | -41.65% |
| EBITDA | -42.30% | -46.91% | -39.63% | -47.62% | -42.07% |
| EPS Basic | 14.86% | 0.77% | -5.32% | -19.06% | -21.76% |
| Normalized Basic EPS | 14.86% | 0.77% | -5.33% | -19.06% | -21.78% |
| EPS Diluted | 14.86% | 0.77% | -5.32% | -19.06% | -21.76% |
| Normalized Diluted EPS | 14.86% | 0.77% | -5.33% | -19.06% | -21.78% |
| Average Basic Shares Outstanding | 57.72% | 45.96% | 34.10% | 23.88% | 14.80% |
| Average Diluted Shares Outstanding | 57.72% | 45.96% | 34.10% | 23.88% | 14.80% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
